1-((R)-amino-cyclopropyl-methyl)-cyclopentanol | 1350712-52-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-((R)-amino-cyclopropyl-methyl)-cyclopentanol
• 英文别名: 1-[(R)-amino(cyclopropyl)methyl]cyclopentan-1-ol
• CAS: 1350712-52-5
• 化学式: C₉H₁₇NO
• 分子量: 155.24
• InChiKey: OPIYMATZFAECHB-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (R)-cyclopropyl-((R)-1-phenyl-ethylamino)-acetic acid 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 10 wt% Pd(OH)2 on carbon 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 甲苯 为溶剂， 100.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 1-((R)-amino-cyclopropyl-methyl)-cyclopentanol
  参考文献：
  名称：

  [EN] PYRROLO [2, 3 - B] PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS
  [FR] DÉRIVÉS DE PYRROLO[2,3-B]PYRAZINE-7-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE JAK ET SYK

  摘要：

  本发明涉及使用式（I）的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3如本文所述定义，其抑制JAK和SYK并且适用于治疗自身免疫和炎症性疾病。

  公开号：

  WO2011144585A1

文献信息

• Pyrrolopyrazine Kinase Inhibitors
  申请人：Hendricks Robert Than

  公开号：US20110288067A1

  公开（公告）日：2011-11-24

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R, R 2 , and R 3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用新型 Formula I 中的吡咯吡嗪衍生物，其中变量 Q 和 R、R2 和 R3 如本文所述定义，这些衍生物抑制 JAK 和 SYK，并用于治疗自身免疫和炎症性疾病。
• PYRROLOPYRAZINE KINASE INHIBITORS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140155376A1

  公开（公告）日：2014-06-05

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R, R 2 , and R 3 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及使用公式I中的新型吡咯吡嗪衍生物，其中变量Q和R，R2和R3的定义如本文所述，它们抑制JAK和SYK，并且对于治疗自身免疫和炎症性疾病是有用的。
• PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2571880A1

  公开（公告）日：2013-03-27
• Deuterium-Enriched Pyrimidine Compounds and Derivatives
  申请人：Dhanoa Daljit Singh

  公开号：US20130040957A1

  公开（公告）日：2013-02-14

  The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof, and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT 1 , 5-HT 1A , 5-HT 2 receptors, 5-HT 2A and 5-HT 2B receptors, dopamine receptors and multiple kinase pathways.